Fig. 1: Clinical efficacy of oncolytic virus therapy combined with anti-PD-1 antibody in liver metastatic colorectal cancer. | Cancer Gene Therapy

Fig. 1: Clinical efficacy of oncolytic virus therapy combined with anti-PD-1 antibody in liver metastatic colorectal cancer.

From: The long-term effectiveness and mechanism of oncolytic virotherapy combined with anti-PD-L1 antibody in colorectal cancer patient

Fig. 1

A Study overview, depicting the treatment protocol for patients with colorectal cancer (CRC). B CT scan at baseline, week 6 and week 12 of responded patient. C Progression-free survival (PFS) and overall survival (OS) of all enrolled patients, the responding patient achieved long progression-free survival (313 days). D Target lesions size changes in four enrolled patients during treatment, the responding patient had a 35.9% tumor remission.

Back to article page